NCT03646461View on ClinicalTrials.gov

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

December 11, 2025

Study Completion Date

December 30, 2025

Conditions
Head and Neck CancerSquamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Ibrutinib 560mg PO daily (Imbruvica)

BTK inhibitor combined with PD-1 inhibitor

DRUG

Cetuximab

Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle

DRUG

Nivolumab

Nivolumab 3mg/kg biweekly 28 day cycle

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

University of California, San Diego

OTHER